4th Quarter - Report

VIATRIS INC. for VIATRIS INC

Firm
Client
Income
—
Expenses
$630,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Drug pricing issues, access to generic medicines, Medicare Part D program and generic drugs Generic drug quality and FDA oversight Part D Formulary Design and Generic Drug Tiering Electronic Labeling of Prescription Drugs FDA facility inspections Medicare incentives for biosimilar utilization Generic Drug User Fee Amendments (GDUFA) Complex Generic Drug Approvals H.R. 3 - Lower Drug Costs Now Act H.R. 2846 - Ensuring Access to Lower-Cost Medicines for Seniors Act Biosimilar interchangeability H.R. 5376 - Build Back Better Act

LobbyistCovered position, as disclosed
KATHARINE HAYES —
DAVID MARIN —
PETER WALLACE —
ANNE WILSON —

Contacted: Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Commerce, Dept of (DOC); SENATE; Centers For Disease Control & Prevention (CDC); Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES

Bills named: H.R. 5376 (117th), H.R. 2846 (117th), H.R. 3 (117th)

Trade (domestic/foreign) TRD

Trade issues related to generic medicines Pharmaceutical supply chain

LobbyistCovered position, as disclosed
KATHARINE HAYES —
DAVID MARIN —
PETER WALLACE —

Contacted: Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); Centers For Disease Control & Prevention (CDC); SENATE; Commerce, Dept of (DOC); Health & Human Services, Dept of (HHS)

Taxation/Internal Revenue Code TAX

Corporate Tax Policy

LobbyistCovered position, as disclosed
DAVID MARIN —
PETER WALLACE —

Contacted: SENATE; Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Commerce, Dept of (DOC); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Centers For Disease Control & Prevention (CDC)

Budget/Appropriations BUD

Medicaid Rebate provision of the Bipartisan Budget Act of 2015

LobbyistCovered position, as disclosed
KATHARINE HAYES —
DAVID MARIN —
PETER WALLACE —
ANNE WILSON —

Contacted: SENATE; Commerce, Dept of (DOC); Centers For Medicare and Medicaid Services (CMS); Office of Management & Budget (OMB); Food & Drug Administration (FDA); Centers For Disease Control & Prevention (CDC); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Financial Institutions/Investments/Securities FIN

Policy related to corporate governance

LobbyistCovered position, as disclosed
DAVID MARIN —

Contacted: Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); SENATE; Centers For Disease Control & Prevention (CDC); Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB)

Copyright/Patent/Trademark CPT

Issues related Inter Partes Review (IPR) process for biosimilars and generic drugs Patent Settlements

LobbyistCovered position, as disclosed
KATHARINE HAYES —
DAVID MARIN —
PETER WALLACE —
ANNE WILSON —

Contacted: Commerce, Dept of (DOC); SENATE; Food & Drug Administration (FDA); Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Centers For Disease Control & Prevention (CDC)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.